In the $3.2 billion market for neuromodulation devices, competition is heating up in the spinal cord stimulation (SCS) segment as device manufacturers armed with new clinical trial data and next-generation technologies disrupt the status quo of standard tonic SCS systems and begin to expand the market, shift market share and boost the revenues of companies both large and small. Innovation is fueling healthy growth in this market, particularly in the US, where the market is projected to grow from around $1.13 billion in 2014 to almost $1.62 billion in 2019, a CAGR of 7.5%.

START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.